Skip to main content
SpringerLink
Log in

Optimizing Unresectable Colorectal Liver Metastases for Surgery—No Limits, Any Benefits?

  • Letter to the Editor
  • Published:
Journal of Gastrointestinal Surgery

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Takahashi S, Konishi M, Kinoshita T et al. Predictors for Early Recurrence After Hepatectomy for Initially Unresectable Colorectal Liver Metastasis. J Gastrointest Surg, (2013).

  2. Lam VW, Spiro C, Laurence JM et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Annals of surgical oncology, 19(4), 1292-1301 (2012).

    Article  PubMed  Google Scholar 

  3. Tsim N, Healey AJ, Frampton AE et al. Two-stage resection for bilobar colorectal liver metastases: R0 resection is the key. Annals of surgical oncology, 18(7), 1939-1946 (2011).

    Article  PubMed  Google Scholar 

  4. Chua TC, Liauw W, Chu F, Morris DL. Summary outcomes of two-stage resection for advanced colorectal liver metastases. Journal of surgical oncology, 107(2), 211-216 (2013).

    Article  PubMed  Google Scholar 

  5. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92(3), 205-216 (2000).

    Article  PubMed  CAS  Google Scholar 

  6. Elias D, De Baere T, Roche A, Mducreux, Leclere J, Lasser P. During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. The British journal of surgery, 86(6), 784-788 (1999).

    Article  PubMed  CAS  Google Scholar 

  7. Mima K, Beppu T, Chikamoto A et al. Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. International journal of clinical oncology / Japan Society of Clinical Oncology, (2012).

  8. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of surgery, 230(3), 309-318; discussion 318-321 (1999).

    Article  PubMed  CAS  Google Scholar 

  9. Mann CD, Metcalfe MS, Leopardi LN, Maddern GJ. The clinical risk score: emerging as a reliable preoperative prognostic index in hepatectomy for colorectal metastases. Archives of surgery, 139(11), 1168-1172 (2004).

    Article  PubMed  Google Scholar 

  10. Ivanecz A, Potrc S, Horvat M, Jagric T, Gadzijev E. The validity of clinical risk score for patients undergoing liver resection for colorectal metastases. Hepato-gastroenterology, 56(94-95), 1452-1458 (2009).

    Google Scholar 

  11. Malik HZ, Prasad KR, Halazun KJ et al. Preoperative prognostic score for predicting survival after hepatic resection for colorectal liver metastases. Annals of surgery, 246(5), 806-814 (2007).

    Article  PubMed  Google Scholar 

  12. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Annals of surgery, 247(1), 125-135 (2008).

    Article  PubMed  Google Scholar 

  13. Mitry E, Fields AL, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26(30), 4906-4911 (2008).

    Article  CAS  Google Scholar 

  14. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 25(13), 1670-1676 (2007).

    Article  CAS  Google Scholar 

  15. Yoshimura K, Uehara K, Tojima Y et al. Optimal schedule of adjuvant chemotherapy with S-1 for stage III colon cancer: study protocol for a randomized controlled trial. Trials, 14, 17 (2013).

    Article  PubMed  CAS  Google Scholar 

  16. Cauchy F, Aussilhou B, Dokmak S et al. Reappraisal of the risks and benefits of major liver resection in patients with initially unresectable colorectal liver metastases. Annals of surgery, 256(5), 746-752; discussion 752-744 (2012).

    Article  PubMed  Google Scholar 

  17. Yamashita Y-i, Adachi E, Toh Y et al. Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases. Surgery Today, 41(4), 526-532 (2011).

    Article  PubMed  Google Scholar 

  18. Malik HZ, Gomez D, Wong V et al. Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. European Journal of Surgical Oncology (EJSO), 33(8), 1003-1009 (2007).

    Google Scholar 

  19. Goere D, Benhaim L, Bonnet S et al. Adjuvant chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: a comparative study between hepatic arterial infusion of oxaliplatin and modern systemic chemotherapy. Annals of surgery, 257(1), 114-120 (2013).

    Article  PubMed  Google Scholar 

Download references

Conflicts of Interest

None declared

Author information

Authors and Affiliations

  1. HPB Surgical Unit, Department of Surgery & Cancer, Imperial College, Hammersmith Hospital campus, Du Cane Road, London, W12 0HS, UK

    Tamara M. H. Gall, Adam E. Frampton & Long R. Jiao

  2. Division of Oncology, Department of Surgery & Cancer, Imperial Centre for Translational and Experimental Medicine (ICTEM), Imperial College, Hammersmith Hospital campus, Du Cane Road, London, W12 0NN, UK

    Jonathan Krell

Authors
  1. Tamara M. H. Gall
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adam E. Frampton
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan Krell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Long R. Jiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Long R. Jiao.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gall, T.M.H., Frampton, A.E., Krell, J. et al. Optimizing Unresectable Colorectal Liver Metastases for Surgery—No Limits, Any Benefits?. J Gastrointest Surg 17, 2185–2187 (2013). https://doi.org/10.1007/s11605-013-2197-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11605-013-2197-2

Keywords

Search

Navigation